Vimarsana
Biggest News Aggregation in the World

Page 24 - Small Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Small Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Small Pharma Today - Breaking & Trending Today

Small Pharma (CVE:DMT) Reaches New 1-Year Low at $0.21 - Vimarsana News

Small Pharma (CVE:DMT) Reaches New 1-Year Low at $0.21

Small Pharma Inc. (CVE:DMT – Get Rating)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.21 and last traded at C$0.21, with a volume of 79732 shares. The stock had previously closed at C$0.22. Separately, Eight Capital set a C$1.00 price objective on Small […]

WuXi Biologics Achieved Record Growth and Profitability in 2021 - Vimarsana News

WuXi Biologics Achieved Record Growth and Profitability in 2021

Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million...

Small Pharma (CVE:DMT) Reaches New 52-Week Low at $0.21 - Vimarsana News

Small Pharma (CVE:DMT) Reaches New 52-Week Low at $0.21

Small Pharma Inc. (CVE:DMT – Get Rating)’s stock price reached a new 52-week low on Monday . The company traded as low as C$0.21 and last traded at C$0.21, with a volume of 203932 shares traded. The stock had previously closed at C$0.24. Separately, Eight Capital set a C$1.00 price objective on shares of Small […]

Small Pharma (CVE:DMT) Reaches New 1-Year Low at $0.21 - Vimarsana News

Small Pharma (CVE:DMT) Reaches New 1-Year Low at $0.21

Small Pharma Inc. (CVE:DMT – Get Rating) reached a new 52-week low during trading on Monday . The stock traded as low as C$0.21 and last traded at C$0.21, with a volume of 203932 shares changing hands. The stock had previously closed at C$0.24. Separately, Eight Capital set a C$1.00 price target on shares of […]

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets - Vimarsana News

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets

10.03.2022 - Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical trials planned for 2022 SPL028, a deuterated DMT candidate with Composition of Matter patent protection in the UK, moves ... Seite 1